Wu Xueyao, Zhang Xiaofan, Hao Yu, Li Jiayuan
Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 16 Ren Min Nan Lu, Chengdu, 610041, Sichuan, People's Republic of China.
Breast Cancer. 2021 Jan;28(1):25-39. doi: 10.1007/s12282-020-01182-0. Epub 2020 Nov 25.
Based on the biological mechanisms underlying the obesity-breast cancer connections, potential protein biomarkers involved in breast cancer development have been identified, which may be helpful for the estimation of breast cancer risk. This study aimed to carry out a comprehensive overview of systematic reviews on circulating levels of obesity-related protein biomarkers for female breast cancer risk to provide a solid reference for potential breast cancer predictors.
Comprehensive literature searches were conducted in MEDLINE, EMBASE and Cochrane Database of Systematic Reviews up to Dec 2019. The AMSTAR tool was used for the methodological quality assessment of the included systematic reviews. Evidence was reported narratively.
A total of 28 relevant systematic reviews which were mostly of moderate quality were included in the overview. Protein biomarkers relating to adipokines, insulin/insulin-like growth factor-1 (IGF-1) axis, inflammatory cytokines and sex hormones were investigated. Higher levels of circulating IGF-1, IGF-binding protein-3, leptin and resistin were found to be associated with an increased risk of premenopausal breast cancer; lower levels of circulating adiponectin and higher levels of circulating c-reactive protein, leptin, and resistin were found to be associated with an increased risk of postmenopausal breast cancer.
We found sufficient evidence on the positive associations between certain obesity-related protein biomarkers with pre- and/or postmenopausal breast cancer risk. These biomarkers could be used jointly as predictors, so as to build a comprehensive risk predictive score for female breast cancer.
CRD42020175328.
基于肥胖与乳腺癌关联的生物学机制，已鉴定出参与乳腺癌发展的潜在蛋白质生物标志物，这可能有助于评估乳腺癌风险。本研究旨在全面概述关于肥胖相关蛋白质生物标志物循环水平与女性乳腺癌风险的系统评价，为潜在的乳腺癌预测指标提供可靠参考。
截至2019年12月，在MEDLINE、EMBASE和Cochrane系统评价数据库中进行了全面的文献检索。使用AMSTAR工具对纳入的系统评价进行方法学质量评估。以叙述方式报告证据。
该综述共纳入28篇相关系统评价，质量大多为中等。研究了与脂肪因子、胰岛素/胰岛素样生长因子-1（IGF-1）轴、炎性细胞因子和性激素相关的蛋白质生物标志物。发现循环IGF-1、IGF结合蛋白-3、瘦素和抵抗素水平升高与绝经前乳腺癌风险增加相关；发现循环脂联素水平降低以及循环C反应蛋白、瘦素和抵抗素水平升高与绝经后乳腺癌风险增加相关。
我们发现有充分证据表明某些肥胖相关蛋白质生物标志物与绝经前和/或绝经后乳腺癌风险之间存在正相关。这些生物标志物可联合用作预测指标，从而构建女性乳腺癌的综合风险预测评分。
PROSPERO注册号：CRD42020175328。
